Download citation file:
From the Center for Rheumatology, Albany, New York; University of California, San Francisco, and Synarc Inc., San Francisco, California; University of Alabama at Birmingham School of Medicine, Birmingham, Alabama; University of Alberta, Edmonton, Alberta, Canada; Leeds General Infirmary, Leeds, United Kingdom; Hospital Central, San Luis Potosi, Mexico; University of Medical Sciences, Wroclaw, Poland; Bristol-Myers Squibb, Princeton, New Jersey; and University Hospital Leuven, Leuven, Belgium.
ClinicalTrials.gov identifier: NTC00048568.
Grant Support: By Bristol-Myers Squibb.
Potential Financial Conflicts of Interest: Employment: T. Li (Bristol-Myers Squibb), Z. Ge (Bristol-Myers Squibb), J.-C. Becker (Bristol-Myers Squibb); Consultancies: J.M. Kremer (Bristol-Myers Squibb), H.K. Genant (Bristol-Myers Squibb, Amgen, Wyeth, Novartis, Lilly, Roche), L.W. Moreland (Bristol-Myers Squibb), A.S. Russell (Bristol-Myers Squibb), P. Emery (Amgen, Schering-Plough, Centocor, Bristol-Myers Squibb), R. Westhovens (Schering-Plough, Bristol-Myers Squibb); Honoraria: J.M. Kremer (Bristol-Myers Squibb), H.K. Genant (Bristol-Myers Squibb, Amgen, Wyeth, Novartis, Lilly, Roche), L.W. Moreland (Bristol-Myers Squibb), P. Emery (Wyeth, Roche), R. Westhovens (Schering-Plough, Bristol-Myers Squibb); Stock ownership or options (other than mutual funds): T. Li (Bristol-Myers Squibb), Z. Ge (Bristol-Myers Squibb), J.-C. Becker (Bristol-Myers Squibb); Grants received: J.M. Kremer (Bristol-Myers Squibb), H.K. Genant (Bristol-Myers Squibb, Amgen, Wyeth, Novartis, Lilly, Roche), L.W. Moreland (Bristol-Myers Squibb); Patents pending: J.-C. Becker (Bristol-Myers Squibb).
Requests for Single Reprints: Joel M. Kremer, MD, Center for Rheumatology, 1367 Washington Avenue, Suite 1, Albany, NY 12206; e-mail, email@example.com.
Current Author Addresses: Dr. Kremer: Center for Rheumatology, 1367 Washington Avenue, Suite 1, Albany, NY 12206.
Dr. Genant: Radiology Department, University of California, San Francisco, 505 Parnassus Avenue, Box 0628, San Francisco, CA 94143-0628.
Dr. Moreland: 068 Spain Rehabilitation Center, University of Alabama at Birmingham, 1717 6th Avenue South, Birmingham, AL 35294.
Dr. Russell: Medical Department, University of Alberta Hospital, 562 Heritage Medical Research Centre, Edmonton, T6G 2S2 Alberta, Canada.
Dr. Emery: Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, United Kingdom.
Dr. Abud-Mendoza: Hospital Central, Av. Carranza 2395, San Luis Potosi, S.L.P. 78240, Mexico.
Dr. Szechinski: Department of Rheumatology, Medical University of Wroclaw, ul. Wiśniowa 36a, 53-137 Wrocław, Poland.
Drs. Li and Becker: Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543.
Dr. Ge: 13133 Taylor Court, West Windsor, NJ 08550.
Dr. Westhovens: Rheumatology Department, University Hospitals, K.U. Leuven, Herestraat 49, 3000 Leuven, Belgium.
Author Contributions: Conception and design: J.M. Kremer, H.K. Genant, L.W. Moreland, A.S. Russell, P. Emery, T. Li, J.-C. Becker, R. Westhovens.
Analysis and interpretation of the data: J.M. Kremer, H.K. Genant, L.W. Moreland, P. Emery, C. Abud-Mendoza, T. Li, Z. Ge, J.-C. Becker, R. Westhovens.
Drafting of the article: J.M. Kremer, H.K. Genant, L.W. Moreland, A.S. Russell, T. Li, J.-C. Becker, R. Westhovens.
Critical revision of the article for important intellectual content: J.M. Kremer, H.K. Genant, L.W. Moreland, A.S. Russell, P. Emery, C. Abud-Mendoza, J. Szechinski, T. Li, J.-C. Becker, R. Westhovens.
Final approval of the article: J.M. Kremer, L.W. Moreland, A.S. Russell, P. Emery, C. Abud-Mendoza, J. Szechinski, J.-C. Becker, R. Westhovens.
Provision of study materials or patients: J.M. Kremer, A.S. Russell, P. Emery, C. Abud-Mendoza, J. Szechinski, R. Westhovens.
Statistical expertise: Z. Ge, J.-C. Becker.
Obtaining of funding: J.-C. Becker.
Administrative, technical, or logistic support: J.-C. Becker.
Collection and assembly of data: J.M. Kremer, P. Emery, J.-C. Becker.
The institutional review boards or independent ethics committees approved a common clinical protocol for each site, and we performed the study in accordance with the ethical principles of the Declaration of Helsinki. All patients provided written informed consent to the study protocol before randomization.
*MTX = methotrexate. Nine abatacept-treated patients and 5 placebo recipients from 1 site were excluded from all efficacy analyses before unblinding due to nonadherence but were included in all safety analyses.
American College of Rheumatology ( ) 20 ( ), ACR 50 ( ), and ACR 70 ( ) responses over 1 year in all patients who received at least 1 dose of the study medication. The percentage of patients who achieved a Health Assessment Questionnaire Disability Index ( ) response (≥0.3-unit improvement from baseline in HAQ-DI) was determined over 1 year. MTX = methotrexate. *Intention-to-treat population where all dropouts were considered to be ACR nonresponders subsequent to their dropout. †Because of adherence issues identified during the study, patients from 1 site were excluded from all efficacy analyses before unblinding but were included in the analysis of safety.
Interquartile range changes from baseline in Genant-modified Sharp erosion, joint-space narrowing ( ), and total scores were evaluated at 1 year or at early termination (if applicable). The median ( ), interquartile range, and 10th and 90th percentiles ( ) are shown. Data shown are from all randomly assigned and treated patients with baseline and follow-up radiography. MTX = methotrexate.
Please read the other comments before posting. Contributors must reveal any conflict
Comments are moderated and will appear on the site at the discretion of The American
College of Physicians editorial staff. Please be sure your email address is
updated in your account, otherwise the American College of Physicians will not be
able to contact you about your comment.
Anyone can submit a comment any time after publication, but only those submitted within 4 weeks of an article’s publication will be considered for print publication. One month after publication, editors review all posted comments and select some for publication in the Letters section of the print version of Annals. (Not peer reviewed)
Authors: No more than 5
Text: Word Limit 400 (excludes references), 5 references, no figures or tables
* = Required Field
Disclosure of Any Conflicts of Interest*
(applies to the past 5 years and foreseeable future) Indicate any potential conflicts
of interest of each author below, including specific financial interests and relationships
and affiliations relevant to the subject matter or materials discussed in the manuscript
(eg, employment/affiliation, grants or funding, consultancies, honoraria, speakers
bureau, stock ownership or options, expert testimony, royalties, donation of medical
equipment, or patents filed, received, or pending). If all authors have none, check
"No potential conflicts or relevant financial interests" in the box below. Please
also indicate any funding received in support of this work. The information will
be posted with your response.
Abatacept for People with Active Rheumatoid Arthritis
The summary below is from the full report titled “Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis. A Randomized Trial.” It is in the 20 June 2006 issue of Annals of Internal Medicine (volume 144, pages 865-876). The authors are J.M. Kremer, H.K. Genant, L.W. Moreland, A.S. Russell, P. Emery, C. Abud-Mendoza, J. Szechinski, T. Li, Z. Ge, J.-C. Becker, and R. Westhovens.
The In the Clinic® slide sets are owned and copyrighted by the American College
of Physicians (ACP). All text, graphics, trademarks, and other intellectual property
incorporated into the slide sets remain the sole and exclusive property of the ACP.
The slide sets may be used only by the person who downloads or purchases them and
only for the purpose of presenting them during not-for-profit educational activities.
Users may incorporate the entire slide set or selected individual slides into their
own teaching presentations but may not alter the content of the slides in any way
or remove the ACP copyright notice. Users may make print copies for use as hand-outs
for the audience the user is personally addressing but may not otherwise reproduce
or distribute the slides by any means or media, including but not limited to sending
them as e-mail attachments, posting them on Internet or Intranet sites, publishing
them in meeting proceedings, or making them available for sale or distribution in
any unauthorized form, without the express written permission of the ACP. Unauthorized
use of the In the Clinic slide sets will constitute copyright infringement.
to gain full access to the content and tools.
Learn more about subscription options